SARS-CoV-2-specific T cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID-19 vaccination

Eur J Immunol. 2022 Jul;52(7):1194-1197. doi: 10.1002/eji.202149771. Epub 2022 Apr 28.

Abstract

Little is known about the cellular immune response to SARS-CoV-2 vaccination in patients after HSCT and B-NHL with iatrogenic B-cell aplasia. In nonseroconverted HSCT patients, induction of specific T-cell responses was assessed. The majority of allogeneic HSCT patients not showing humoral responses to vaccination also fail to mount antigen-specific T-cell responses.

Keywords: HSCT; SARS-CoV-2; SARS-CoV-2-specific T cells; vaccination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral
  • COVID-19 Vaccines
  • COVID-19*
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunity, Cellular
  • Immunity, Humoral
  • SARS-CoV-2
  • T-Lymphocytes
  • Vaccination

Substances

  • Antibodies, Viral
  • COVID-19 Vaccines